REFERENCES
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC 2008: 112–114.
- Liso V, Bennet J. Morphological and cytochemical characteristics of leukaemic promyelocytes. Best Pract Res Clin Heamatol 2003; 16: 349–355.
- Albano F, Mestice A, Pannunzio A et al. The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34- CD2- hyper-granular (M3) and microgranular (M3v,) phenotypes. Haematologica 2006; 91: 311–316.
- Bennet J, Catovsky D, Daniel M, Flandrin G, Galton D, Gralnick H. Proposals for the classification of acute leukemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451–458.
- Bennet J, Catovsky D, Daniel M, Flandrin G, Galton D, Gralnick H. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British co-operative group. Ann Intern Med 1985; 103:620–625.
- Avvisati G, Lo Coco F, Diverio D et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia:A Gruppo Italian° Malattie Ema-tologische Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390–1398.
- Whang Z, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111:2505–2515.
- Haferlach T, Kohlmann A, Schnittger S, et al. AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes. Genes Chromosomes Cancer 2005; 43: 113–127.
- Stasi R, Bruno A, Venditti A et al. A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype. Leuk Res 1997; 21: 575–580.
- Gabert J, Beillard E, Van der Velden VHJ et al. Standardization and quality con-trol of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: A Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.
- Gallagher RE, Willman C, Slack JL et al. Association of PML-RARa Fusion mRNA Type With Pretreatment Hematologic Characteristics But Not Treatment Out-come in Acute Promyelocytic Leukemia: An Intergroup Molecular Study. Blood 1997; 90: 1656–1663.
- Guglielmi C, Martelli MP, Diverio D et al. Immunophenotype of adult and child-hood acute promyelocytic leukemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol 1998; 102: 1035–1041.
- Earle VL, Ross F, Fisher A et al. Haemopoietic growth factors significantly improve the mitotic index and chromosome quality in cytogentic cultures of myeloid neoplasia. Genes Chromosomes Cancer 2007; 46: 670–674.
- Foley R, Soamboonsrup P, Carter RF et al. CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphol-ogy, expression of CD2 and bcr3 isoform. Am J Hematol 2001; 67: 34–41.
- Lee JJ, Cho D, Chung IJ et al. CD34 expression is associated with poor clinical outcome in patients with acute promyelocytic leukemia. Am J Hematol 2003; 73: 149–153.
- Grimwade D, Enver T. Review: Acute promyelocytic leukemia: where does it stem from? Leukemia 2004; 18: 375–384.
- Mantadakis E, Samonis G, Kalmanti M. A comprehensive review of acute pro-myelocytic leukemia in children. Acta haematol 2008; 119:73–82.
- Murray CK, Esty E, Paietta E et al. CD56 expression in acute promyelocytic leukemia: a possible indicator for poor treatment outcome. J Clin Oncol 1999; 17: 293–297.